Page 64 - DIFDUF

719
The ability of antibodies to deplete target cells was dependent
examined how to enhance antibody functions in this setting.
PERFECTOR
as a model of chronic infection, wieland and colleagues
infections. Using lymphocytic choriomeningitis virus (LCMV)
can thus be severely impaired in individuals with chronic
of immune complexes. The actions of antibody-based drugs
often associated with increased generation and deposition
Persistent immune activation during chronic infections is
giving antibodies a boost
Disseminated fungal lesions seen on
131118-COHANIM - 131118-COHANIM | 1 - A | 18-11-13 | 11:24:13 | SR:-- | Cyan
#131118-COHANIM - 131118-COHANIM | 1 - A | 18-11-13 | 11:24:13 | SR:-- | Black
131118-COHANIM - 131118-COHANIM | 1 - A | 18-11-13 | 11:24:13 | SR:-- | Yellow
Clearly it is of invaluable importance to
131118-COHANIM - 131118-COHANIM | 1 - A | 18-11-13 | 11:24:13 | SR:-- | Magenta
#
LETTERS Eitan Israeli Case CommuniCations Sci Immunol 2018; 3: eaao3125 children. Clin Transl Imaging 2016; 4: 57-72. Glaudemans AW. Imaging fungal infections in infections. Clin Microbiol Infect 2011; 17: 409-17. with [ 18 F]fluorodeoxyglucose for invasive fungal contribution of positron emission tomography 2014; 203: 180-9. patients with fungal infections. AJR Am J Roentgenol Kumar R. Potential role of 18F-FDG PET/CT in infection.

2 Department of General Internal Medicine, colorectal oncogenesis and progression of patients with chronic atrophic gastri- Israel Medical Association Journal
University Hospital Inselspital Bern, Bern, by causing a possible chronic inflamma- tis; however, positive histology was only
Switzerland tory mucosal damage, thereby promoting apparent in 33% of the subjects [3]. There Vol 20, Number 11, November 2018 ISSN 1565-1088
3 First Department of Pharmacology, Medical
School, Aristotle University of Thessaloniki, colorectal (CRC) invasion, metastasis, and are a few other possible physiopathological
Thessaloniki, Greece mortality. H. pylori positive CRC patients mechanisms for the association between
4 Department of Gastroenterology, 401 General undergoing positron emission tomogra- Hp-I and complicated colorectal neoplasia.
Military Hospital of Athens, Athens, Greece
[jannis@auth.gr; ancoratus2010@gmail.com] phy/computed tomography (PET/CT) Large prospective studies with additional
imaging had a higher rate of metastatic measurements of possible mediators would
References disease associated with a higher mortality be desirable.
1. Shmuely H, Brenner B, Groshar D, et al. The rate [1]. As for the possibility that current 707 The use of FDG PET/CT in the diagnosis and
association of Helicobacter pylori seropositivity with Hp-I induces humoral and cellular immune Haim Shmuely MD , Baruch Brenner MD , ORIGINAL ARTICLES
2,6
1,5
all-cause mortality among colorectal cancer patients 3,6 4 monitoring of disseminated aspergillosis
undergoing PET/CT scans. IMAJ 2018; 20: 504-8. responses that provoke potential oncogenic David Groshar MD , Nir Hadari MD , 665 Adverse drug event rate in Israeli hospitals: O. Shovman
2,6
3,6
2. Kountouras J, Polyzos SA, Doulberis M, et al. sequelae including metastases and mortal- Ofer Purim MD , Meital Nidam MD , validation of an international trigger tool
Potential impact of Helicobacter pylori-related meta- ity, we agree with Dr. Kountouras, and we Merab Eligalashvili MD , Jacob Yahav MD and an international comparison study
1,5
3,6
bolic syndrome on upper and lower gastrointestinal made this point clear in our article [1]. and Hanna Bernstine MD 3,6
םישורד חול
tract oncogenesis. Metabolism 2018; 87: 18-24. E. Zimlichman, I. Gueta, D. Daliyot, A. Ziv, B. Oberman, CASE COMMUNICATIONS
3. Kountouras J, Kapetanakis N, Zavos C, et. al. We demonstrated [2] that fecal shedding 1 Department of Internal Medicine D and O. Hochman, O. Tamir, O. Tal and R. Loebstein
Impact of Helicobacter pylori infection on colon of viable H. pylori and H. pylori antigens Helicobacter Research Institute, Kaplan Medical 709 Treatment of resistance to thyroid hormone in
oncogenesis. Am J Gastroenterol 2013; 108: 625-6. occurs, under certain circumstances, and Center, Rehovot, Israel 670 Hoarding among Jewish Holocaust survivors: pregnancy: how to address the challenge
4. Refaeli R, Chodick G, Haj S, Goren S, Shalev V, are detected in the stool. We agree that 2 Institute of Oncology, Davidoff Cancer Center and moving toward a theoretical model E. Chertok-Shacham, E. Chervinsky and A. Ishay
Muhsen K. Relationships of H. pylori infection and 3 Department of Nuclear Medicine, Rabin Medical B.S. Porat-Katz, S. Rachman-Elbaum, I. Katz and T.W. Johnson
its related gastroduodenal morbidity with metabolic histology is the gold standard for current Center (Beilinson Campus), Petah Tikva, Israel 712 Pyoderma gangrenosum and extensive aseptic
syndrome: a large cross-sectional study. Sci Rep 2018; Hp-I diagnosis, nevertheless, as discussed 4 674 Surgical biopsy of pathologically enlarged lymph chest wall abscess in a patient with
8: 4088. Dan District, Clalit Health Services, Or Yehuda, Israel
in our article [1], measurement of circu- 5 Faculty of Medicine, Hebrew University, Jerusalem, nodes: a reappraisal inflammatory bowel disease
lating H. pylori antibodies by an ELISA Israel T. Dorfman, M. Neymark, J. Begal and Y. Kluger I. Snast, I. Ostfeld, L. Pavlovsky, E. Hodak
test is sensitive and specific for detecting 6 Sackler Faculty of Medicine, Tel Aviv University, and A. Gafter-Gvili
The Association of Helicobacter H. pylori infection. Serology may remain Tel Aviv, Israel 679 Clinical and Molecular Characteristics of Eight Israeli 714 ASIA syndrome following breast implant placement
[hshmuely@zahav.net.il]
pylori Seropositivity and positive even after curing the infection. The Families With Thyroid Hormone Receptor Beta Mutations R. Fenoglio, I. Cecchi and D. Roccatello
Colorectal Cancer latter is an advantage, as the past infection References E. Zaig, O. Cohen-Ouaknine, A. Tsur, S. Nagar, G. Bril, L. Tolkin,
A. Cahn, M. Heyman and B. Glaser
may be even more important for carcino- 1. Shmuely H, Brenner B, Groshar D, et al. The 717 Detection of disseminated aspergillosis on FDG
association of Helicobacter pylori seropositivity with
To the Editor: genesis. H. pylori antibodies may persist in all-cause mortality among colorectal cancer patients 687 Factors associated with recurrence of PET/CT in a patient with acute lymphoblastic
e thank Dr. Kountouras and col- patients with chronic H. pylori infection undergoing PET/CT scans. IMAJ 2018; 20: 504-8. tracheoesophageal fistula (TEF) leukemia (see editorial page 707)
w leagues for their comments, which over decades or throughout life, even if 2. Parsonnet J, Shmuely H, Haggerty T. Fecal and V. Nir, M. Gur, Y. Toukan, F. Hakim, A. Vachyan and L. Bentur N. Hod, R. Anconina, D. Levin, E. Tiktinsky, D. Ezroh Kazap,
I. Levi, M. Zektser, V. Stavi, G. Sebbag and S. Lantsberg
oral shedding of Helicobacter pylori from healthy
are published in this issue of the Israel H. pylori is no longer detectable in biopsy infected adults. JAMA 1999; 282: 2240-5. 691 Short-term adherence with discharge
Medical Association Journal (IMAJ). specimens. In patients treated with antise- 3. Karnes WE, Samloff IM, Siurala M, et al. Positive recommendation for insulin treatment
We agree with them that Helicobacter cretory drugs, H. pylori antibodies persist. serum antibody and negative tissue staining for among patients with type 2 diabetes IMAGES
Helicobacter pylori in subjects with chronic atrophic
pylori infection (Hp-I) has an impact on Positive antibody levels were found in 86% body gastritis. Gastroenterology 1991; 101: 167-74. S. Koren, M. Yoshpa, R. Koren, D. Cantrell and M.J. Rapoport
720 Post-myocardial infarction ventricular septal defect:
695 NOD2/CARD15 mutations among Bedouin still a deadly complication 30 years after
Capsule Arabs with inflammatory bowel disease: the first transcatheter closure

frequency and phenotype correlation
F. Rey, T. Ronchard, J. Chaara and S. Noble
N. Abu Freha, W. Badarna, M. Abu Tailakh, H. Abu Kaf, A. Fich,
D. Schwartz, A Segal, J. Elkrinawi and A. Karban
Calmanervin-DR-03-05/17 Cancer treatment by immune checkpoint blockade (ICB) can They also modeled factors that excluded T cell infiltration into REVIEWS 054-7568656
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
CONFERENCE SUMMARY
tumors using expression signatures from immunosuppressive
bring long lasting clinical benefits, but only a fraction of
722 Patient involvement in the design and policy in
cells. Using this framework and pre-treatment RNA-Seq or
patients respond to treatment. To predict ICB response, Jiang
roni@mediafarm.co.il
et al. developed TIDE, a computational method to model
Conference on Therapeutic Patient Education
of anti-nuclear antibodies between the Elia CTD
two primary mechanisms of tumor immune evasion: the NanoString tumor expression profiles, TIDE predicted the 700 Comparison of the clinical utility in the detection healthcare: highlights from the 4th Annual
outcome of melanoma patients treated with first-line anti-
B6
Screen and indirect immunofluorescence on
in Diabetes OTZMA, 21 March 2018
induction of T cell dysfunction in tumors with high infiltration PD1 or anti-CTLA4 more accurately than other biomarkers Hep-2 cells: a review of the literature V. Kalamaro, K. Harshkop, R. Lipner and O. Tamir
of cytotoxic T lymphocytes (CTL) and the prevention of T cell such as PD-L1 level and mutation load. TIDE also revealed C. Robier, O. Amouzadeh-Ghadikolai, M. Stettin and G. Reicht
B1
infiltration in tumors with low CTL level. The authors identified new candidate ICB resistance regulators, such as SERPINB9,
signatures of T cell dysfunction from large tumor cohorts by demonstrating utility for immunotherapy research. 725 LETTERS
Valerian, Passiflora, Vitamin B6,Vitamin B1
testing how the expression of each gene in tumors interacts Nature Med 2018; 24: 1550 EDITORIAL תורדתסהה
with the CTL infiltration level to influence patient survival. Eitan Israeli לארשיב תיאופרה
703 Primary immunodeficiency: the Israeli connection
Israeli Medical
A. Etzioni Association
w w w.medit ec .c o.il
726 1-800-800-678